Related Experiment Video
Updated: May 21, 2026
09:02
An Experimental Model to Study Tuberculosis-Malaria Coinfection upon Natural Transmission of Mycobacterium tuberculosis and Plasmodium berghei
Published on: February 17, 2014
Models of prophylaxis.
Erik Berntorp1, Kathelijn Fischer, Alec Miners
1Lund University, Malmö Centre for Thrombosis and Haemostasis, Skåne University Hospital, Malmö, Sweden. erik.berntorp@med.lu.se
Summary
Long-term prophylaxis for hemophilia, initiated decades ago, is now standard care. While high-dose regimens show modest outcome improvements, ongoing studies compare strategies to optimize treatment and economic justification.
Area of Science:
- Hematology
- Public Health
- Health Economics
Background:
- Continuous prophylaxis for hemophilia emerged in Sweden and The Netherlands during the mid-20th century.
- High costs and study design challenges delayed widespread adoption of prophylaxis as best practice.
- Prospective randomized trials in 2007 and 2011 validated findings from earlier European cohort studies.
Purpose of the Study:
- To compare different prophylactic treatment strategies in hemophilia.
- To investigate the long-term clinical outcomes and socioeconomic parameters associated with various prophylaxis regimens.
- To provide insights into the economic justification and cost-effectiveness of hemophilia prophylaxis.
Main Methods:
- Retrospective analysis of Swedish and Dutch hemophilia cohorts with differing prophylaxis strategies.
- Ongoing prospective comparison of treatment, clinical outcomes, clotting factor consumption, and socioeconomic factors.
- Review of existing studies on the economic justification of prophylaxis, noting variations in results.
Main Results:
- Retrospective comparisons suggest high-dose, costly prophylaxis regimens offer a modest improvement in outcomes.
- Current research focuses on optimizing prophylaxis initiation, dosage, and cessation.
- Economic justification studies yield varied results due to differing definitions, costs, and methodologies.
Conclusions:
- High-dose hemophilia prophylaxis provides some benefit, but the improvement is not dramatic.
- Further prospective studies are needed to fully understand the long-term consequences and optimal strategies for prophylaxis.
- The cost-effectiveness of hemophilia prophylaxis remains debated, influenced by multiple methodological factors.
Related Concept Videos
01:25Models of Health Promotion and Illness Prevention I
A model is a theoretical way to understand a concept or an idea. Models can overcome barriers to health regardless of diverse economic and cultural backgrounds. In addition, models make the task easier by providing different ways to approach complex issues. There are two major health promotion models: the health belief model and the health promotion model.
The health belief model (HBM) attempts to predict health-related behavior in specific belief patterns. According to the HBM, a person's...
The health belief model (HBM) attempts to predict health-related behavior in specific belief patterns. According to the HBM, a person's...
01:29Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
01:20Pharmacokinetic Models: Overview
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
01:27Pharmacodynamic Models: Overview
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
01:18Models of Health Promotion and Illness Prevention II
The person's health status fluctuates continually, varying from being in good health to becoming ill and returning to being healthy. To understand the concept of illness prevention, there are two models. First, the health-illness continuum model is a graphic representation of an individual's wellness. It states that a person is considered healthy in the absence of physical disease and the presence of good emotional health.
The agent-host-environment model states that disease results from...
The agent-host-environment model states that disease results from...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).